調査・レポート
2026年9月5日•1分で読めます
Pharmacies Use Claude Design to Create AI‑Powered Patient Brochures
Pharmacies find standard pharma pamphlets insufficient and use Claude Design to convert AI‑gathered content into printable A4 brochures.
調査・レポート
2026年9月4日•1分で読めます
DA Information Renames to DAI, Targets AI‑Based Business Transformation
DA Information, an IT subsidiary of Dong‑A Socio Group, has changed its name to DAI and announced a shift from system maintenance to AI‑driven decision‑making support as an AX innovation partner.
調査・レポート
2026年9月2日•1分で読めます
Insilico Medicine and China Medical System Holdings Sign $1.77B CNS Co‑Development Deal
Insilico Medicine and China Medical System Holdings have agreed to a 12 billion‑yuan (≈$1.77 billion) partnership to co‑develop central nervous system therapies using Insilico’s PandaOmics AI platform.
調査・レポート
2026年9月2日•1分で読めます
Eli Lilly and Novo Nordisk Lead AI Platform Citations Among Pharma Companies
Eli Lilly and Novo Nordisk top AI platform citations, surpassing Merck, AbbVie, J&J and Pfizer, driven by GLP‑1 therapy interest.
調査・レポート
2026年9月1日•1分で読めます
Korean Pharmaceutical Association Launches AI‑Driven Public Outreach and Pharmacy Support Platforms
The Korean Pharmaceutical Association announced the launch of 'PharmSNS' for pharmacist‑public communication and the formation of a working group to develop AI tools for pharmacy workflow efficiency.
調査・レポート
2026年9月1日•1分で読めます
AI Chatbots Mirror Social Bias Toward Mental Illness and HIV Patients, Study Finds
A study by Beijing University researchers published in Nature Health shows AI chatbots like ChatGPT, Claude, and DeepSeek reflect societal prejudice against people with mental disorders and HIV.
調査・レポート
2026年9月1日•1分で読めます
AI Pharmacy Automation ‘AX Zone’ to Debut at 2026 Gwangju Pharmacist Conference
The 2026 Gwangju Pharmacist Academic Conference will feature an ‘AX Zone’ where participants can experience AI‑driven pharmacy automation, including compounding, inventory, counseling, and management.
調査・レポート
2026年8月31日•1分で読めます
Samsung Bioepis, Proteina Expand AI Antibody Development
Samsung Bioepis and Proteina signed a license option agreement to advance AI‑driven antibody drug discovery from candidate identification to commercialization, building on a government AI project.
調査・レポート
2026年8月30日•1分で読めます
AI in Pharma Faces Data‑Gathering Delays, Not Scientific Limits
A recent note says most of the two‑week deviation investigation time is spent on data collection, not science, highlighting a bottleneck for AI tools in pharma.
調査・レポート
2026年8月30日•1分で読めます
LG Chem teams up with LabGenius Therapeutics to speed AI-driven multi‑antibody cancer drug discovery
LG Chem announced a partnership with UK AI drug‑development firm LabGenius Therapeutics to jointly discover multi‑antibody cancer drug candidates using AI and automated experiments.
調査・レポート
2026年8月30日•1分で読めます
Generative AI Expands into Pharmacy Education and Practice, Study Shows
A recent Inje University study finds generative AI rapidly spreading in health education, with limited current use in pharmacy curricula but growing interest among universities and practicing pharmacists.
調査・レポート
2026年8月30日•1分で読めます
SK Biopharm Partners with Insilico Medicine on AI-Driven CNS Drug Discovery
SK Biopharm has signed a joint R&D agreement with AI-driven Insilico Medicine to develop CNS therapeutics, focusing on neuroimmune targets, announced at the 2026 Bio International Convention.